GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss, often 15 to 20 percent of body weight. A significant portion of that loss can be lean mass, sometimes 25 to 40 percent of total weight lost. This article reviews the evidence on muscle preservation during GLP-1 therapy and the strategies that may reduce lean mass loss.
Why GLP-1 Agonists Cause Muscle Loss
Weight loss from any method includes both fat and lean tissue. GLP-1 agonists reduce appetite and caloric intake sharply. When energy deficit is large, the body breaks down muscle protein for fuel. In the STEP 1 trial, participants on semaglutide lost an average of 15.2 kg, of which 6.9 kg was lean mass. That is 45 percent of total loss. A 2024 meta-analysis of 18 trials found that GLP-1 users lost 2.1 kg more lean mass than placebo users at the same weight loss. This is a 2 of 3 on evidence quality.
Rapid weight loss worsens muscle loss. Losing more than 1 kg per week increases the proportion of lean mass lost. GLP-1 agonists often produce that rate in the first months. Older adults and people with sarcopenia are at higher risk. Baseline muscle mass predicts functional decline after weight loss.
Protein Intake and Muscle Preservation
Higher protein intake during energy restriction preserves lean mass. A 2020 systematic review found that 1.2 to 1.6 g of protein per kg of body weight per day reduced lean mass loss by 27 percent compared to lower intakes. For an 80 kg person, that is 96 to 128 g daily. This is a 2 of 3 on evidence quality.
Protein distribution matters. Consuming 25 to 30 g of high-quality protein per meal stimulates muscle protein synthesis maximally. Many GLP-1 users eat small meals due to appetite suppression. They may get only 10 to 15 g per meal. Protein supplements or high-protein foods at each meal can help. Leucine-rich sources like whey, dairy, and soy are most effective.
Resistance Training as the Primary Countermeasure
Resistance training is the strongest intervention to preserve muscle during weight loss. A 2021 meta-analysis of 21 trials found that combining resistance exercise with energy restriction reduced lean mass loss by 93 percent compared to diet alone. Participants lost 0.4 kg lean mass with training versus 5.6 kg without. This is a 3 of 3 on evidence quality.
Frequency and volume matter. Two to three sessions per week, with 6 to 10 exercises targeting major muscle groups, is sufficient. Progressive overload is key. GLP-1 users may have low energy, but even one session per week reduces lean mass loss. Bodyweight exercises, resistance bands, or weight machines all work.
Pharmacologic Adjuncts: Testosterone and Myostatin Inhibitors
Testosterone therapy in men with low testosterone preserves lean mass during weight loss. A 2017 trial in obese men on a very low calorie diet found that testosterone reduced lean mass loss by 1.5 kg over 10 weeks. This is a 2 of 3 on evidence quality. Testosterone is not approved for muscle preservation in GLP-1 users and carries risks.
Myostatin inhibitors like bimagrumab increased lean mass by 4.5 percent in a phase 2 trial of obese adults. But no myostatin inhibitor is approved for this use. Selective androgen receptor modulators (SARMs) are investigational. None are approved for muscle preservation during weight loss.
Monitoring and Individualization
Body composition assessment is important. DEXA scans measure lean mass accurately, but are not always accessible. Bioelectrical impedance is less accurate but can track trends. Clinicians should monitor for functional decline: grip strength, gait speed, and sit-to-stand tests. Weight loss rate should be adjusted if lean mass loss exceeds 25 percent of total loss.
Older adults need more aggressive intervention. Those over 65 lose more lean mass during weight loss. Protein intake should be at the high end, 1.5 g/kg or more. Resistance training should be supervised initially. GLP-1 dose can be titrated more slowly to reduce early rapid loss.
Closing Observations
GLP-1 agonists are effective for weight loss, but muscle loss is a real concern. The evidence is strongest for resistance training and adequate protein. Pharmacologic adjuncts remain investigational. Clinicians should individualize monitoring and adjust therapy based on body composition and function. Future research should test combined interventions in GLP-1 users specifically.